Search results for "Neoplasms."

showing 10 items of 7882 documents

Response to the Letter to the editor regarding “Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carc…

2021

therapyCancer ResearchCarcinoma HepatocellularLetter to the editorbusiness.industryLiver Neoplasmshepatocellular carcinomamedicine.diseaseNeoplasm ProteinsGene Expression Regulation NeoplasticOncologyHepatocellular carcinomaCancer researchHumansMedicineStress ProteinsbusinessCancer Letters
researchProduct

Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy

2015

Recently, many studies explored the role of inflammation parameters in the prognosis of urinary cancers, but the results were not consistent. The modified Glasgow Prognostic Score (mGPS), a systemic inflammation marker, is a prognostic marker in various types of cancers. The aim of the present study was to investigate the usefulness of the preoperative mGPS as predictor of recurrence-free (RFS), overall (OS), and cancer-specific (CSS) survivals in a large cohort of urothelial bladder cancer (UBC) patients.A total of 1037 patients with UBC were included in this study with a median follow-up of 22 months (range 3-60 months). An mGPS = 0 was observed in 646 patients (62.3%), mGPS = 1 in 297 pa…

to-lymphocyte ratioAdultMaleRiskmedicine.medical_specialtyPrognosimedicine.medical_treatmentCystectomyGastroenterologySettore MED/24 - UrologiaCystectomyMedicine (all); c-reactive protein; advanced urothelial carcinoma; to-lymphocyte ratioc-reactive proteinRetrospective StudieInternal medicine80 and overHumansMedicineStage (cooking)advanced urothelial carcinomaRetrospective StudiesAgedAged 80 and overModified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience.Univariate analysisBladder cancerbusiness.industryProportional hazards modelMedicine (all)Hazard ratioBladder cancer Radical cystectomyRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryNeoplasm RecurrenceLocalUrinary Bladder NeoplasmsUrinary Bladder NeoplasmCohortFemaleNeoplasm Recurrence LocalAdult; Aged; Aged 80 and over; Female; Humans; Male; Middle Aged; Neoplasm Recurrence Local; Prognosis; Retrospective Studies; Risk; Urinary Bladder Neoplasms; Cystectomy; Medicine (all)businessHumanMedicine
researchProduct

Evaluation of Surgical Outcomes of Abdominal Radical Hysterectomy and Total Laparoscopic Radical Hysterectomy for Cervical Cancer: A Retrospective An…

2022

Although a surgical approach is one of the key treatments for stages IA1-IIA2, results of the Laparoscopic Approach to Cervical Cancer (LACC) published in 2018 radically changed the field, since minimally invasive surgery was associated with a four-fold higher rate of recurrence and a six-fold higher rate of all-cause death compared to an open approach. We aimed to evaluate surgical outcomes of abdominal radical hysterectomy (ARH) and total laparoscopic radical hysterectomy (TLRH) for cervical cancer, including data collected before the LACC trial. In our retrospective analysis, operative time was significantly longer in TLRH compared to ARH (p < 0.0001), although this disadvantage could…

total laparoscopic radical hysterectomycervical cancerHealth Toxicology and Mutagenesiscervical cancer; abdominal radical hysterectomy; total laparoscopic radical hysterectomy; minimally invasive surgery; surgical outcomesPublic Health Environmental and Occupational HealthUterine Cervical NeoplasmsHysterectomysurgical outcomesSettore MED/40 - Ginecologia E OstetriciaTreatment Outcomeabdominal radical hysterectomyHumansLaparoscopyFemaleabdominal radical hysterectomy; cervical cancer; minimally invasive surgery; surgical outcomes; total laparoscopic radical hysterectomy; Female; Humans; Retrospective Studies; Neoplasm Staging; Hysterectomy; Treatment Outcome; Uterine Cervical Neoplasms; Laparoscopyminimally invasive surgeryNeoplasm StagingRetrospective StudiesInternational Journal of Environmental Research and Public Health; Volume 19; Issue 20; Pages: 13176
researchProduct

Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma

2020

Osteolytic bone disease is the major complication associated with the progression of multiple myeloma (MM). Recently, extracellular vesicles (EVs) have emerged as mediators of MM-associated bone disease by inhibiting the osteogenic differentiation of human mesenchymal stem cells (hMSCs). Here, we investigated a correlation between the EV-mediated osteogenic inhibition and MM vesicle content, focusing on miRNAs. By the use of a MicroRNA Card, we identified a pool of miRNAs, highly expressed in EVs, from MM cell line (MM1.S EVs), expression of which was confirmed in EVs from bone marrow (BM) plasma of patients affected by smoldering myeloma (SMM) and MM. Notably,we found that miR-129-5p, whic…

transcription factor sp1.Cancer ResearchBone diseaseosteogenic differentiationexosomeslcsh:RC254-282transcription factor sp1ArticleSettore MED/15 - Malattie Del SangueSettore BIO/13 - Biologia Applicatamedicinemultiple myeloma (MM)ChemistrySettore BIO/16 - Anatomia UmanaMesenchymal stem cellALPLOsteoblastMicroRNAExtracellular vesiclemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSettore CHIM/08 - Chimica FarmaceuticaCell biologymicroRNAsExosomemedicine.anatomical_structureOncologyCell cultureAlkaline phosphatasebone diseaseBone marrowextracellular vesicles (EVs)Cancers
researchProduct

Trends in Net Survival from Vulvar Squamous Cell Carcinoma in Italy (1990–2015)

2023

(1) Objective: In many Western countries, survival from vulvar squamous cell carcinoma (VSCC) has been stagnating for decades or has increased insufficiently from a clinical perspective. In Italy, previous studies on cancer survival have not taken vulvar cancer into consideration or have pooled patients with vulvar and vaginal cancer. To bridge this knowledge gap, we report the trend in survival from vulvar cancer between 1990 and 2015. (2) Methods: Thirty-eight local cancer registries covering 49% of the national female population contributed the records of 6274 patients. Study endpoints included 1- and 2-year net survival (NS) calculated using the Pohar-Perme estimator and 5-year NS condi…

trendvulvar neoplasmvulvar neoplasmsGeneral MedicineSettore MED/42 - Igiene Generale E Applicatavulvar neoplasms; survival; trendsurvivalJournal of Clinical Medicine
researchProduct

Divergent Patterns and Trends in Breast Cancer Incidence, Mortality and Survival Among Older Women in Germany and the United States

2020

Background: Breast cancer treatment has changed tremendously over the last decades. In addition, the use of mammography screening for early detection has increased strongly. To evaluate the impact of these developments, long-term trends in incidence, mortality, stage distribution and survival were investigated for Germany and the United States (US). Methods: Using population-based cancer registry data, long-term incidence and mortality trends (1975&ndash

trendsCancer ResearchUnited States ; Survival ; Trends ; Mortality ; Incidence ; Breast cancer ; GermanyBreast cancer mortalityPopulationsurvivallcsh:RC254-282Article03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerGermanyMedicine030212 general & internal medicineStage (cooking)Mortality trendseducationeducation.field_of_studyRelative survivalbusiness.industryIncidence (epidemiology)lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasemortalityUnited StatesCancer registryOncology030220 oncology & carcinogenesisincidencebusinessDemographyCancers
researchProduct

Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments

2021

Muscle wasting, i.e., cachexia, frequently occurs in cancer and associates with poor prognosis and increased morbidity and mortality. Anticancer treatments have also been shown to contribute to sustainment or exacerbation of cachexia, thus affecting quality of life and overall survival in cancer patients. Pre-clinical studies have shown that blocking activin receptor type 2 (ACVR2) or its ligands and their downstream signaling can preserve muscle mass in rodents bearing experimental cancers, as well as in chemotherapy-treated animals. In tumor-bearing mice, the prevention of skeletal and respiratory muscle wasting was also associated with improved survival. However, the definitive proof tha…

tumorCachexiaActivin ReceptorsActivin Receptors Type IIMyostatinReviewchemotherapymulti-organType IIsurvivalCachexiaNeoplasmsmedicineRespiratory muscleHumansActivins; Cancer cachexia; Chemotherapy; Mortality; Multi-organ; Muscle wasting; Myostatin; Survival; Tumor; Activin Receptors Type II; Cachexia; Humans; Neoplasms; Signal Transduction; Survival Analysislcsh:QH301-705.5Wastingsoluviestintäbiologysyöpähoidotbusiness.industryactivinsCancerSkeletal musclemuscle wastingGeneral MedicineActivin receptormedicine.diseaseSurvival AnalysismortalityBlockademedicine.anatomical_structurelcsh:Biology (General)myostatinCancer researchbiology.proteinproteiinitmedicine.symptombusinesshenkiinjääminenlihassurkastumasairaudetSignal Transductioncancer cachexia
researchProduct

Extracellular Vesicles as Shuttles of Tumor Biomarkers and Anti-Tumor Drugs

2014

Extracellular vesicles (EV) include vesicles released by either normal or tumor cells. EV may exceed the nanometric scale (microvesicles), or to be within the nanoscale, also called exosomes. Thus, it appears that only exosomes and larger vesicles may have the size for potential applications in nanomedicine, in either disease diagnosis or therapy. This is of particular interest for research in cancer, also because the vast majority of existing data on EV are coming from pre-clinical and clinical oncology. We know that the microenvironmental features of cancer may favor cell-to-cell paracrine communication through EV, but EV have been purified, characterized, and quantified from plasma of tu…

tumorsCancer Researchbusiness.industryVesicleParacrine CommunicationbiomarkersCancerexosomeslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensBioinformaticsmedicine.diseaselcsh:RC254-282Extracellular vesiclesMicrovesiclesAnti-Tumor DrugsteranosticsTumor BiomarkersOncologyPerspective ArticleCancer researchmedicineNanomedicineextracellular vesiclesbusinessFrontiers in Oncology
researchProduct

Comparative histological and immunohistochemical study of ameloblastomas and ameloblastic carcinomas

2017

Background This study aimed to compare the histological and immunohistochemical characteristics of ameloblastomas (AM) and ameloblastic carcinomas (AC). Material and Methods Fifteen cases of AM and 9 AC were submitted to hematoxilin and eosin (H&E) and immunohistochemical analysis with the following antibodies: cytokeratins 5,7,8,14 and 19, Ki-67, p53, p63 and the cellular adhesion molecules CD138 (Syndecan-1), E-cadherin and β-catenin. The mean score of the expression of Ki-67 and p53 labelling index (LIs) were compared between the groups using the t test. A value of p<0.05 was considered to be statistically significant. Results All cases were positive for CKs 5, 14 and 19, but negative fo…

tumorsMalePathologyAntibodies Neoplasmameloblastic carcinomaMalignant transformation0302 clinical medicineAmeloblastomaChildp63biologyki-67Middle Aged:CIENCIAS MÉDICAS [UNESCO]ImmunohistochemistryJaw Neoplasms030220 oncology & carcinogenesisKi-67immunohistochemistryUNESCO::CIENCIAS MÉDICASImmunohistochemistry//purl.org/pe-repo/ocde/ford#3.02.11 [https]Femalesyndecan-1 cd138Adultmedicine.medical_specialtyAdolescentgovernment.form_of_governmentcateninMalignancyAmeloblastoma03 medical and health sciencesYoung AdultDentistry Oral Surgery & MedicineexpressionmedicineHumansgeneGeneral DentistryOral Medicine and PathologyCadherinResearchcytokeratinsodontogenic030206 dentistrymedicine.disease//purl.org/pe-repo/ocde/ford#3.02.14 [https]Ameloblastic carcinomaOtorhinolaryngologyCateningovernmentbiology.proteinSurgeryodontogenic-tumorse-cadherin
researchProduct

Could PD-1/PDL1 immune checkpoints be linked to HLA signature?

2019

The outstanding clinical expansion of monoclonal antibodies (mAbs) to programmed cell death receptor-1 (PD-1) (nivolumab and pembrolizumab) and PD-1 ligand-1 (PDL-1) (atezolizumab, avelumab and durvalumab) has received an increasing level of interest regarding immunotherapy and multidrug combinations, for the treatment of a number of common human malignancies. Some patients treated with these agents receive remarkable benefits in term of quality of life, progression-free (PFS) and overall survival (OS). However, a significant percentage of these patients experience immune-related adverse events (irAEs), while others present with an ultra-rapid disease progression, defined as hyperprogressio…

vDrug-Related Side Effects and Adverse ReactionsProgrammed Cell Death 1 ReceptorImmunologyAntibodies Monoclon alHuman leukocyte antigenB7-H1 AntigenImmune systemHLA AntigensirAENeoplasmsHumansImmunology and AllergyMedicinePD-1/PDL-1-blockadebusiness.industryAntibodies MonoclonalBiomarkerProgrammed Cell Death 1 ReceptorSignature (logic)HaplotypesOncologyImmunologyoutcomeImmunotherapyHLA alleleDrug-Related Side Effects and Adverse ReactionbusinessBiomarkersB7-H1 AntigenImmunotherapy
researchProduct